Dr. Timothy H. Elder, M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 641
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
FL license ME110985
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uf Health Shands Hospital Gainesville, FL
- HCA Florida North Florida Hospital Gainesville, FL
- HCA Florida Lake City Hospital Lake City, FL
Medical groups
- Lake Area Physical Therapy Inc. (384 clinicians)
- Simedhealth LLC (91 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 641
- Services billed
- 7,330
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 856 | 374 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 355 | 301 |
| Blood test, lipids (cholesterol and triglycerides) | 331 | 285 |
| Blood test, comprehensive group of blood chemicals | 315 | 286 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 267 | 106 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 227 | 227 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 223 | 96 |
| Hemoglobin a1c level | 208 | 142 |
| Established patient office or other outpatient visit, 20-29 minutes | 183 | 138 |
| Annual depression screening, 5 to 15 minutes | 179 | 179 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $540,053 in research payments for these studies, mostly to the institutions running them.
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared…
AstraZeneca Pharmaceuticals LP - A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
Sanofi Pasteur Inc. · Completed · NCT06361875 - A phase IIb,randomized,double blind,placebo controlled study to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of clostridioides difficile infection in individuals 18 years of age and above
AstraZeneca Pharmaceuticals LP - Real-world effectiveness of mepolizumab in treating chronic obstructiv
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.